ArticleEuropean stroke journal2022
Validation of the UK English Oxford cognitive screen-plus in sub-acute and chronic stroke survivors.
Article in European stroke journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Do Current Endpoints Underestimate Benefit in MeVO Stroke? A Call for Cognitive Profiling.Clinical neuroradiology · 2026Article
- The Queen Square cognitive assessment screen (Q-CAS): normative data and validation in acute stroke.Journal of neurology · 2026Article
- Comparison of the Tele-Oxford Cognitive Screen to a neuropsychological battery in chronic stroke survivors.Journal of neuropsychology · 2026Article
- Beyond cognition in post-stroke cognitive impairment: neuropsychiatric symptoms and stroke-specific cognitive screening.Cerebral circulation - cognition and behavior · 2026Article
- The mini-Oxford cognitive screen (Mini-OCS): A very brief cognitive screen for use in chronic stroke.European stroke journal · 2026Article
- The mini-Oxford cognitive screen (Mini-OCS): A very brief cognitive screen for use in chronic stroke.European stroke journal · 2025Article
- Quality of Assessment Tools for Aphasia: A Systematic Review.Brain sciences · 2025Review
- Assessing neurocognitive functioning among adults ageing with and without HIV at the Kenyan Coast: measurement issues and correlates.Frontiers in aging neuroscience · 2025Article
- Article
- Predictive, preventive and personalized project of vascular cognitive impairment in China (P3): Study design and interim baseline patient characteristics of a Nationwide multicenter prospective registry.Aging medicine (Milton (N.S.W)) · 2024Article
- Association of Neuroimaging Markers on Clinical CT Scans With Domain-Specific Cognitive Impairment in the Early and Later Poststroke Stages.Neurology · 2023Article
- Using Multiverse Analysis to Highlight Differences in Convergent Correlation Outcomes Due to Data Analytical and Study Design Choices.Assessment · 2023Article
- Article
- Rasch validation of a new scale to measure dependency in arm use in daily life: the Upper Limb Lucerne ICF-based Multidisciplinary Observation Scale.Frontiers in neurology · 2023Article
- Characterization of neurocognitive deficits in patients with post-COVID-19 syndrome: persistence, patients' complaints, and clinical predictors.Frontiers in psychology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: Stroke survivors are routinely screened for cognitive impairment with tools that often fail to detect subtle impairments. The Oxford Cognitive Screen-Plus (OCS-Plus) is a brief tablet-based screen designed to detect subtle post-stroke cognitive impairments. We examined its psychometric properties in two UK English-speaking stroke cohorts (subacute: <3 months post-stroke, chronic: >6 months post-stroke) cross-sectionally. Patients and methods: This study included 347 stroke survivors (mean age = 73 years; mean education = 13 years; 43.06% female; 74.42% ischaemic stroke). The OCS-Plus was completed by 181 sub-acute stroke survivors and 166 chronic stroke survivors. All participants also completed the Oxford Cognitive Screen (OCS) and a subset completed the Montreal Cognitive Assessment (MoCA) and further neuropsychological tests. Results: First, convergent construct validity of OCS-Plus tasks to task-matched standardized neuropsychological tests was confirmed ( Discussion and conclusion: The OCS-Plus provides a valid screening tool for sensitive detection of subtle cognitive impairment in stroke patients. Indeed, the OCS-Plus detected subtle cognitive impairment at a similar level to validated neuropsychological assessments and exceeded detection of cognitive impairment compared to standard clinical screening tools.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.